We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-21.35%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.43B
AUM Growth
-$314M
Cap. Flow
+$224M
Cap. Flow %
9.21%
Top 10 Hldgs %
48.1%
Holding
447
New
130
Increased
120
Reduced
90
Closed
66

Top Buys

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$38.8M
2
BIIB icon
Biogen
BIIB
+$26M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$23.3M
4
VTRS icon
Viatris
VTRS
+$21M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$16.2M

Top Sells

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$28.9M
2
MRK icon
Merck
MRK
+$17.9M
3
XOM icon
ExxonMobil
XOM
+$14.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$13.4M
5
LPCN icon
Lipocine
LPCN
+$7.13M

Sector Composition

Rank Sector Weight
1 Miscellaneous 82.86%
2 Healthcare 14.52%
3 Energy 1.33%
4 Technology 0.46%
5 Materials 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
326
CALL
Alkermes
ALKS
$7.72B
$260K 0.01%
+537
New +$35.5K
NDRM
327
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$257K 0.01%
+12,416
New +$255K
BIOL
328
DELISTED
Biolase, Inc.
BIOL
$255K 0.01%
23
-1
-4% -$18.6K
BDSI
329
CALL
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$255K 0.01%
458
– –
INFI
330
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$254K 0.01%
+30,000
New +$277K
INFI
331
PUT
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$254K 0.01%
300
– –
CLDX icon
332
PUT
Celldex Therapeutics
CLDX
$3.02B
$251K 0.01%
16
-101
-86% -$28.6K
ADVM
333
PUT
DELISTED
Adverum Biotechnologies
ADVM
$247K 0.01%
+30
New +$3.83K
MGNX icon
334
CALL
MacroGenics
MGNX
$257M
$244K 0.01%
+114
New +$3.58K
IMDZ
335
DELISTED
Immune Design Corp.
IMDZ
$244K 0.01%
+20,000
New +$375K
CASI
336
DELISTED
CASI Pharmaceuticals
CASI
$217K 0.01%
20,254
-4,066
-17% -$58.5K
AMRN
337
PUT
Amarin Corp
AMRN
$294M
$216K 0.01%
56
– –
CDMO
338
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$215K 0.01%
1,558
-8,096
-84% -$67.6K
APEN
339
DELISTED
Apollo Endosurgery, Inc.
APEN
$213K 0.01%
14,106
+10,617
+304% +$202K
BHC icon
340
Bausch Health
BHC
$2.12B
$209K 0.01%
+1,171
New +$273K
EYEGW
341
DELISTED
Eyegate Pharmaceuticals, Inc. Warrants
EYEGW
$204K 0.01%
+200,000
New +$247K
APDNW
342
DELISTED
Applied DNA Sciences Inc Warrant
APDNW
$196K 0.01%
63,310
-142,037
-69% -$236K
PRSN
343
DELISTED
PERSEON CORP COM STK NEW (DE)
PRSN
$177K 0.01%
+569,985
New +$485K
MNKD icon
344
MannKind Corp
MNKD
$1.14B
$173K 0.01%
10,760
-18,701
-63% -$397K
OCUL icon
345
CALL
Ocular Therapeutix
OCUL
$2.24B
$162K 0.01%
+115
New +$2.31K
EXEL icon
346
PUT
Exelixis
EXEL
$14.1B
$157K 0.01%
280
-734
-72% -$3.99K
IMUX icon
347
Immunic
IMUX
$141M
$156K 0.01%
+97
New +$485K
NSPR icon
348
InspireMD
NSPR
$36.1M
– –
0
– –
SCPX
349
DELISTED
Scorpius Holdings, Inc.
SCPX
– –
0
– –
SKBI
350
DELISTED
SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV)
SKBI
$141K 0.01%
147,926
-8,100
-5% -$13K
12 13
14
15 16

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2015 Portfolio in Review

As of Q3 2015, Sabby Management held 447 positions worth $2.43B, down 11% from $2.74B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Sabby Management deployed $224M of net new capital in Q3 2015, opening 130 new positions and adding to 120 existing holdings. Its largest new stake was iShares Russell 2000 ETF: 327,168 shares worth $35.7M.

By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, down from 89% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was Lipocine, an estimated $7.13M trimmed.

  • Sabby Management's largest Q3 2015 buy was iShares Russell 2000 ETF: 327,168 shares worth $35.7M.
  • Sabby Management added most to Mobileye N.V. in Q3 2015, an estimated $8.9M increase.
  • Sabby Management's biggest Q3 2015 reduction was Lipocine, cutting an estimated $7.13M.
  • Sabby Management fully exited iShares 20+ Year Treasury Bond ETF in Q3 2015, selling an estimated $28.9M.
  • Sabby Management's ten largest holdings make up 48% of its $2.43B portfolio in Q3 2015.
  • Sabby Management opened 130 new positions and closed 66 in Q3 2015.
  • Sabby Management's portfolio value fell 11% quarter-over-quarter to $2.43B.

Based on Sabby Management's 13F filing for Q3 2015, filed 16 Nov 2015.